Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Neil Campbell
Senior Counsel
Neil counsels clients in a variety of strategic and transactional matters relating to drug and device development and manufacturing, licensing and collaboration, service arrangements, academic agreements, and technology evaluation agreements.
Prior to starting his legal career, Neil spent a decade as a biomedical researcher. In that role, he gained a deep scientific and industry context that enables him to appreciate clients’ scientific development strategies and provide them with thoughtful and pragmatic counsel.
Neil regularly helps clients navigate complex multinational supply chain and clinical trial arrangements for small molecule and biologic products, including cell and gene therapies.
Neil regularly helps clients navigate complex multinational supply chain and clinical trial arrangements for small molecule and biologic products, including cell and gene therapies.
More about Neil
Life Sciences Transactions Associate
Reed Smith LLP
Representation of public and private pharmaceutical and biotechnology companies, ranging from startups to multinational corporations in the US, Europe, and Japan, in a broad range of life sciences transactional matters, including drafting and negotiating of CRO agreements, clinical trial agreements, license agreements, collaboration agreements, develop-ment and commercialization agreements, supply agreements, master services agreements, material transfer agreements, manufacturing agreement, SAAS agreements, and quality agreements.
Preclinical Imaging Shared Resource Manager
Rutgers Cancer Institute of New Jersey
CMC and Clinical Development
- Counseled clinical development stage company in negotiating multiple complex agreements for its CAR-T product supply chain
- Representation of early-stage drug development accelerator company in development and supply agreements for its gene therapy treatment for a rare genetic disorder
- Provided strategic legal counseling to multiple drug development companies in connection with large, multicenter, global Phase 2 and 3 clinical studies for small molecule and biologic products
- Negotiation of sponsored research and other agreements with academic institutions in the USA, EU, and UK
Licensing and Strategic Transaction
- Representation of early-stage drug development companies in research collaborations to discover and/or generate multispecific or conjugated antibodies against designated drug targets
- ONK Therapeutics’ license and collaboration with Intellia to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M plus royalties
- Immunocore Holdings’s research and development collaboration with Gaeta B.V. to develop gamma delta (γδ) TCR-based immunotherapies for solid tumors, with an option for Immunocore to exclusively license candidates resulting from the collaboration
- Alnylam’s License Agreement with Agios for novel siRNA for potential treatment of polycythemia vera
Alumni Steering Committee
Rutgers Center for Corporate Law and Governance
Neil is a member of the Alumni Steering Committee for the Rutgers Center for Corporate Law and Governance.
Life Sciences Transactions Associate
Reed Smith LLP
Representation of public and private pharmaceutical and biotechnology companies, ranging from startups to multinational corporations in the US, Europe, and Japan, in a broad range of life sciences transactional matters, including drafting and negotiating of CRO agreements, clinical trial agreements, license agreements, collaboration agreements, develop-ment and commercialization agreements, supply agreements, master services agreements, material transfer agreements, manufacturing agreement, SAAS agreements, and quality agreements.
Preclinical Imaging Shared Resource Manager
Rutgers Cancer Institute of New Jersey
CMC and Clinical Development
- Counseled clinical development stage company in negotiating multiple complex agreements for its CAR-T product supply chain
- Representation of early-stage drug development accelerator company in development and supply agreements for its gene therapy treatment for a rare genetic disorder
- Provided strategic legal counseling to multiple drug development companies in connection with large, multicenter, global Phase 2 and 3 clinical studies for small molecule and biologic products
- Negotiation of sponsored research and other agreements with academic institutions in the USA, EU, and UK
Licensing and Strategic Transaction
- Representation of early-stage drug development companies in research collaborations to discover and/or generate multispecific or conjugated antibodies against designated drug targets
- ONK Therapeutics’ license and collaboration with Intellia to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M plus royalties
- Immunocore Holdings’s research and development collaboration with Gaeta B.V. to develop gamma delta (γδ) TCR-based immunotherapies for solid tumors, with an option for Immunocore to exclusively license candidates resulting from the collaboration
- Alnylam’s License Agreement with Agios for novel siRNA for potential treatment of polycythemia vera
Alumni Steering Committee
Rutgers Center for Corporate Law and Governance
Neil is a member of the Alumni Steering Committee for the Rutgers Center for Corporate Law and Governance.
Related Content
Interested in working with Neil?
Our team is eager to learn more about your project